OBJECTIVES: To study serum levels of vascular endothelial growth factor (VEGF), a potent angiogenic factor, during distinct periods of the female life span and compare them with corresponding levels of age-matched males. It is hypothesized that VEGF might be increased at periods of enhanced angiogenesis. METHODS: Venous blood was drawn from healthy females (n = 59) and males (n = 53) divided into six groups: fetuses (cord blood), neonates, children, adults (same females in the proliferative and secretory phases of their menstrual cycle), pregnant, and elderly (postmenopausal). Serum VEGF levels were measured by an enzyme immunoassay. RESULTS: Females showed 49% higher serum VEGF levels than males (t = 2.74, P = .01). Cord and neonatal blood levels were significantly increased compared with those of adults (t = 2.41, P = .02, and t = 5.81, P = .0001, respectively). All female age groups presented higher serum VEGF levels than the group of women in the proliferative phase of the cycle; nevertheless, VEGF levels in the secretory phase did not differ (t = 1.85, P = .07). CONCLUSIONS: Serum VEGF levels are higher in females than in males and during life periods characterized by enhanced growth and development, implying increased rates of angiogenesis.
OBJECTIVES: To study serum levels of vascular endothelial growth factor (VEGF), a potent angiogenic factor, during distinct periods of the female life span and compare them with corresponding levels of age-matched males. It is hypothesized that VEGF might be increased at periods of enhanced angiogenesis. METHODS: Venous blood was drawn from healthy females (n = 59) and males (n = 53) divided into six groups: fetuses (cord blood), neonates, children, adults (same females in the proliferative and secretory phases of their menstrual cycle), pregnant, and elderly (postmenopausal). Serum VEGF levels were measured by an enzyme immunoassay. RESULTS: Females showed 49% higher serum VEGF levels than males (t = 2.74, P = .01). Cord and neonatal blood levels were significantly increased compared with those of adults (t = 2.41, P = .02, and t = 5.81, P = .0001, respectively). All female age groups presented higher serum VEGF levels than the group of women in the proliferative phase of the cycle; nevertheless, VEGF levels in the secretory phase did not differ (t = 1.85, P = .07). CONCLUSIONS: Serum VEGF levels are higher in females than in males and during life periods characterized by enhanced growth and development, implying increased rates of angiogenesis.
Authors: Gunnel Hellgren; Chatarina Löfqvist; Anna-Lena Hård; Ingrid Hansen-Pupp; Magnus Gram; David Ley; Lois E Smith; Ann Hellström Journal: Pediatr Res Date: 2015-09-15 Impact factor: 3.756
Authors: Rajan Jain; Patricia L Robertson; Dheeraj Gandhi; Sachin K Gujar; Karin M Muraszko; Stephen Gebarski Journal: AJNR Am J Neuroradiol Date: 2005-05 Impact factor: 3.825
Authors: Wolfgang Lieb; Radwan Safa; Emelia J Benjamin; Vanessa Xanthakis; Xiaoyan Yin; Lisa M Sullivan; Martin G Larson; Holly M Smith; Joseph A Vita; Gary F Mitchell; Douglas B Sawyer; Ramachandran S Vasan Journal: Eur Heart J Date: 2009-02-17 Impact factor: 29.983
Authors: Gabriëlla A M Blokland; Jakob Grove; Chia-Yen Chen; Chris Cotsapas; Stuart Tobet; Robert Handa; David St Clair; Todd Lencz; Bryan J Mowry; Sathish Periyasamy; Murray J Cairns; Paul A Tooney; Jing Qin Wu; Brian Kelly; George Kirov; Patrick F Sullivan; Aiden Corvin; Brien P Riley; Tõnu Esko; Lili Milani; Erik G Jönsson; Aarno Palotie; Hannelore Ehrenreich; Martin Begemann; Agnes Steixner-Kumar; Pak C Sham; Nakao Iwata; Daniel R Weinberger; Pablo V Gejman; Alan R Sanders; Joseph D Buxbaum; Dan Rujescu; Ina Giegling; Bettina Konte; Annette M Hartmann; Elvira Bramon; Robin M Murray; Michele T Pato; Jimmy Lee; Ingrid Melle; Espen Molden; Roel A Ophoff; Andrew McQuillin; Nicholas J Bass; Rolf Adolfsson; Anil K Malhotra; Nicholas G Martin; Janice M Fullerton; Philip B Mitchell; Peter R Schofield; Andreas J Forstner; Franziska Degenhardt; Sabrina Schaupp; Ashley L Comes; Manolis Kogevinas; José Guzman-Parra; Andreas Reif; Fabian Streit; Lea Sirignano; Sven Cichon; Maria Grigoroiu-Serbanescu; Joanna Hauser; Jolanta Lissowska; Fermin Mayoral; Bertram Müller-Myhsok; Beata Świątkowska; Thomas G Schulze; Markus M Nöthen; Marcella Rietschel; John Kelsoe; Marion Leboyer; Stéphane Jamain; Bruno Etain; Frank Bellivier; John B Vincent; Martin Alda; Claire O'Donovan; Pablo Cervantes; Joanna M Biernacka; Mark Frye; Susan L McElroy; Laura J Scott; Eli A Stahl; Mikael Landén; Marian L Hamshere; Olav B Smeland; Srdjan Djurovic; Arne E Vaaler; Ole A Andreassen; Bernhard T Baune; Tracy Air; Martin Preisig; Rudolf Uher; Douglas F Levinson; Myrna M Weissman; James B Potash; Jianxin Shi; James A Knowles; Roy H Perlis; Susanne Lucae; Dorret I Boomsma; Brenda W J H Penninx; Jouke-Jan Hottenga; Eco J C de Geus; Gonneke Willemsen; Yuri Milaneschi; Henning Tiemeier; Hans J Grabe; Alexander Teumer; Sandra Van der Auwera; Uwe Völker; Steven P Hamilton; Patrik K E Magnusson; Alexander Viktorin; Divya Mehta; Niamh Mullins; Mark J Adams; Gerome Breen; Andrew M McIntosh; Cathryn M Lewis; David M Hougaard; Merete Nordentoft; Ole Mors; Preben B Mortensen; Thomas Werge; Thomas D Als; Anders D Børglum; Tracey L Petryshen; Jordan W Smoller; Jill M Goldstein Journal: Biol Psychiatry Date: 2021-03-23 Impact factor: 12.810